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Abstract
Background: Head and neck squamous cell carcinoma (HNSCC) is the sixth leading cancer worldwide. They are
typically characterized by a high incidence of local recurrence, which is the most common cause of death in
HNSCC patients. TP53 is the most frequently mutated gene in HNSCC and patients carrying TP53 mutations are
associated with a higher probability to develop local recurrence. MiRNAs, which are among the mediators of the
oncogenic activity of mt-p53 protein, emerge as an appealing tool for screening, diagnosis and prognosis of cancer.
We previously identified a signature of 12 miRNAs whose aberrant expression associated with TP53 mutations and
was prognostic for HNSCC. Among them miR-96-5p emerges as an oncogenic miRNAs with prognostic significance
in HNSCC.
Methods: To evaluate the oncogenic role of miR-96-5p in a tumoral context, we performed colony formation, cell
migration and cell viability assays in two HNSCC cell lines transfected for miR-96-5p mimic or inhibitor and treated
with or without radio/chemo-therapy. In addition, to identify genes positively and negatively correlated to miR-96-
5p expression in HNSCC, we analyzed the correlation between gene expression and miR-96-5p level in the subset
of TCGA HNSCC tumors carrying missense TP53 mutations by Spearman and Pearson correlation. To finally identify
targets of miR-96-5p, we used in silico analysis and the luciferase reporter assay to confirm PTEN as direct target.
Results: Our data showed that overexpression of miR-96-5p led to increased cell migration and radio-resistance,
chemotherapy resistance in HNSCC cells. In agreement with these results, among the most statistically significant
pathways in which miR-96-5p is involved, are focal Adhesion, extracellular matrix organization and PI3K-Akt-mTOR-
signaling pathway. As a direct target of miR-96-5p, we identified PTEN, the main negative regulator of PI3K-Akt
signalling pathway activation.
Conclusions: These results highlight a new mechanism of chemo/radio-resistance insurgence in HNSCC cells and
support the possibility that miR-96-5p expression could be used as a novel promising biomarker to predict radiotherapy
response and local recurrence development in HNSCC patients. In addition, the identification of pathways in which miR-
96-5p is involved could contribute to develop new therapeutic strategies to overcome radio-resistance.
Keywords: miRNAs, TP53 mutations, miR-96-5p, Head and neck cancer, Local recurrence, Migration, Radiotherapy,
Chemotherapy, PTEN, PI3K-Akt signalling pathway
* Correspondence: safarian@khayam.ut.ac.ir; federica.ganci@ifo.gov.it;
giovanni.blandino@ifo.gov.it
2Cell and Molecular Biology Department, School of Biology, College of
Science, University of Tehran, Tehran 1417614411, Iran
1Oncogenomics and Epigenetics Unit, IRCCS-Regina Elena National Cancer
Institute, 00144 Rome, Italy
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Vahabi et al. Journal of Experimental & Clinical Cancer Research          (2019) 38:141 
https://doi.org/10.1186/s13046-019-1119-x
Background
Head and neck cancers are the sixth leading cancer
worldwide and they are represented mainly by the squa-
mous cell carcinoma (HNSCC) occurring in the oral
cavity, pharynx, or larynx [1–4].
They are typically characterized by a high incidence of
local recurrences, which are the most common cause of
death in HNSCC patients, taking place in 60% of cases
[5, 6]. The current standard therapies are surgical and
medical treatment followed by adjuvant radiotherapy
(RT) with or without chemotherapy. Unfortunately, ad-
vances in treatments for HNSCC over the past two de-
cades have not improved overall disease outcomes [7, 8]
and radio and chemo-resistance (intrinsic or acquired)
remain one of the major challenges in the current ther-
apy of HNSCC.
Additionally, the TNM staging system, used to classify
HNSCC patients, does not adequately address the molecu-
lar heterogeneity of HNSCC tumors and patients with the
same TNM stages have a heterogeneous response to ther-
apy [9]. This indicates the need to obtain a more detailed
molecular characterization in order to improve our under-
standing of radio and chemo-resistance mechanisms, to
identify biomarkers for early detection of local recurrence
and treatment response. However, although several mole-
cules can potentially predict response to therapy and clin-
ical outcome in HNSCC, to date, no biomarkers have been
definitively introduced in the clinical practice. Mutation in
TP53 tumour suppressor gene is the most frequently de-
tectable genetic alteration (about 70–80%) reported in
HNSCC [10, 11]. Several evidences show that mutant p53
protein is one of the main players involved in radio/che-
mo-resistance insurgence and it generally predicts poor
outcome and treatment failure in HNSCC patients [12–15].
In addition to TP53 gene, among the best promising bio-
markers, miRNAs, are considered as an appealing tool for
screening, diagnosis and prognosis of cancer [16–19]. miR-
NAs are small non-coding RNA (17–22 nucleotides) which
function as post transcriptional regulators of target gene ex-
pression through interaction with mainly 3’UTR of target
mRNAs [20]. The deregulation of miRNA expression with
oncogenic or tumor suppressor function in several diseases,
including HNSCC cancer, has been reported [19, 21]. One
of the emerging miRNAs as oncogene and biomarker in
HNSCC is miR-96-5p [22, 23].
In our previous studies, we demonstrated that the ex-
pression of miR-96-5p is associated to TP53 status and
its high expression level, individually and in combination
with other miRNAs, was able to predict local recurrence
independently from other clinical co-variables either in
tumors or in histologically tumor-free peritumoral tissue
[14, 15, 24].
In this study, we aim at deeply characterizing the
oncogenic activity of miR-96-5p in HNSCC cells
carrying mutant TP53 gene, focusing the attention in
particular on its role in radio/chemo-resistance, for
which no evidences are present.
We demonstrate that miR-96-5p is up-regulated in
tumor versus normal tissues in two different HNSCC
cohorts of patients and we confirm that this
up-regulation is significantly stronger in patients carry-
ing TP53 mutations than the wild type group. Next, we
show that overexpression of miR-96-5p in the HNSCC
cells carrying mutant p53 protein leads to increased cell
migration, and, finally, we provide the first evidence that
miR-96-5p is involved in radio- and chemo-therapy re-
sistance, at least in part, by directly targeting PTEN
mRNA and maintaining aberrantly activated the
PI3K-AKT pathway.
Materials and methods
Cell lines and culture conditions
Cal 27, FaDu and H1299 cell lines were obtained from
ATCC (Rockville, MD, USA). These cells were cultured in
RPMI-1640 medium (Invitrogen-GIBCO, Carlsbad, CA)
supplemented with 10% fetal bovine serum, penicillin (100
U/mL), and streptomycin (100mg/mL; Invitrogen-GIBCO).
All cell lines were grown at 37 °C in a balanced air humidi-
fied incubator with 5% CO2. All cell lines were tested by
PCR/IF for Mycoplasma presence.
Cell transfection
mirVana™ miRNA mimic negative control #1 (Ambion)
or hsa-miR-96-5p mirVana™ miRNA mimic (Ambion #
4464066) at final concentration of 5 nM for over expres-
sion of miR-96-5p and mirVana™ miRNA inhibitor nega-
tive control #1 or has-miR-96-5p mirVana™ miRNA
inhibitor (Ambion # 4464084) at final concentration of
10 nM for depletion the miR-96-5p expression were
transfected into HNSCC cell lines (Cal 27, FaDu) using
Lipofectamine RNAiMAX (Invitrogen) according to the
manufacturer’s instructions. To decrease PTEN expres-
sion, a siRNA PTEN (5′ GCUACCUGUUAAAG
AAUCA 3′ and, siRNA SCR 5′ CUAUAACGGCGCUC
GAUAUTT 3′, eurofins genomics) were used and trans-
fected with RNAiMAX into the HNSCC cells.
RNA extraction and microRNA expression analysis
Total RNA was extracted using the TRIZOL Reagents
(GIBCO) following the manufacturer’s instructions. The
concentration and purity of total RNA was assessed
using a Nanodrop TM1000 spectrophotometer (Nano-
drop Technologies, Wilmington, DE, USA). 30 ng of
total RNA was reverse transcribed using the TaqMan
microRNA Reverse Transcription Kit (Thermo Fisher
Scientific). Real time-PCR of miRNA expression was car-
ried out in a final volume of 10 ul using ABI Prism 7000
Sequence Detection System (Thermo Fisher Scientific).
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The PCR Reactions were initiated with a 10 min incuba-
tion at 95 °C followed by 40 cycles of 95 °C for 15 s and
60 °C for 60s. qRT-PCR quantification of miRNA expres-
sion was performed using TaqMan MicroRNA® Assays
(Thermo Fisher Scientific) according to the manufac-
turer’s protocol. RNU44 and RNU48 were used as en-
dogenous control to normalize miRNA expression. All
reactions were performed in triplicate.
Cell viability assay
Viability of treated cells was assessed using ATPlite assay
(Perkin Elmer, Massachusetts, USA) at the indicated time
points, accordingly to the manufacturer’s instructions. Cells
(8 × 10^2 cells) were seeded in 96 well-plates and cultured
for 24–48–72-96 h. Each plate was evaluated immediately
on a microplate reader (Expire Technology, Perkin Elmer).
Dual luciferase reporter assay
Wild type 3’UTR of PTEN was cloned in to the
psi-CHECK2 vector (a kind gift from Dr. Pier Paolo Pan-
dolfi) Next, H1299 cells were co-transfected in 24-well
dishes using Lipofectamine 2000 (Invitrogen) with 100 ng
of PTEN-3′-UTR (wt)-Luciferase vectors (psiCHECK-2,
Promega), 100 ng of PTEN-CDS-psi-CHECK2 vector and
20 nM mir-Vana™ miRNA Mimic Negative Control #1
(Ambion) or hsa-miR-96-5p mirVana™ miRNA Mimic
(Ambion # 4464066). Cells were harvested 48 h
post-transfection and luciferase activities were analyzed by
the dual-luciferase reporter assay system (Promega, Madi-
son, WI) in the GloMax 96 Microplate Luminometer
(Promega). Each sample was transfected in duplicate. Each
experiment was repeated in triplicate.
Lysate preparation and immunoblotting analysis
Cells were lysed in buffer with 50mM Tris–HCl pH 8,
with 1% NP-40 (IgepalAC-630) 150mM NaCl, 5 mM
EDTA and fresh protease inhibitors. Extracts were soni-
cated for 10 s and centrifuged at 12000× rpm for 10 min
to remove cell debris. Protein concentrations were deter-
mined by colorimetric assay (Bio-Rad). Western blotting
was performed using the following primary antibodies:
mouse monoclonal anti-Nucleolin (Abcam # ab13541),
rabbit monoclonal anti-PTEN (Cell Signaling # 9552),
rabbit monoclonal anti-AKT (Cell Signaling # 4685),
rabbit monoclonal anti-P-AKT serin473 (Cell Signaling
#4058). Secondary antibodies used were goat anti-mouse
and goat anti-rabbit, conjugated to horseradish peroxid-
ase (Amersham Biosciences,Piscataway, NJ). Immuno-
stained bands were detected by chemiluminescent
method (Pierce, Rockford, IL).
Transwell migration assay
Migration assay was performed using a 24-well plate
with a non-coated 8-mm pore size filter in the insert
chamber (Falcon). Cells were transfected with mirVana™
miRNA Mimic Negative Control #1 (Ambion) or
hsa-miR-96-5p mirVana™ miRNA Mimic (Ambion #
4464066), for miR-96-5p depletion we used mirVana™
miRNA Inhibitor Negative Control #1 or hsa-miR-96-5p
mir- Vana™ miRNA Inhibitor (Ambion # 4464084) at
final concentration of 10 nM. For PTEN depletion, we
used 0.1 uM siSCR or siPTEN (Eurofins genomics). 48 h
after transfection, HNSCC cells were resuspended in
RPMI media with 1% FBS and seeded into the insert
chamber. Cal 27 and FaDu cells were allowed to migrate
for 48 h or 72 h into the bottom chamber containing 0.7
ml RPMI media containing 10% FBS in a humidified in-
cubator at 37 °C in 5% CO2. Migrated cells that attached
to the outside of the filter were visualized by staining
with DAPI and counted.
Clonogenic assays
Cal 27 and FaDu cell lines were transfected with mirVana™
miRNA mimic negative control #1 (Ambion) or
hsa-miR-96-5p mirVana™ miRNA mimic (Ambion #
4464066) and mirVana™ miRNA inhibitor negative control
#1 or has-miR-96-5p mirVana™ miRNA inhibitor (Ambion
# 4464084). 48 h after transfection, cells were detached and
seeded at 500–1500 cells/well into 6-well dishes (Falcon) in
drug-free media. Fresh media (25%) was added every three
days. Colonies were stained with crystal violet and colonies
(> 50 cells) counted after 10–14 days.
Bioinformatic analysis of TCGA dataset
As validation set, we used TCGA head and neck squa-
mous cell carcinoma (TCGA Research Network: http://
cancergenome.nih.gov/). Normalized TCGA HNSC data
were obtained from http://gdac.broadinstitute.org/
(https://doi.org/10.7908/C11G0KM9).
miRNA deregulation was assessed by paired or unpaired
Student’s t-test. Significance was defined at the P < 0.05
level.
Kaplan–Meier analysis
Local recurrence-free survival was evaluated using
Kaplan–Meier analysis and Cox proportional hazard re-
gression model. Intensity levels of tumoral samples were
divided in three subgroups and survival analysis was
conducted by comparing the highest values with the
medium and low subgroups. The log-rank test was used
to evaluate differences between curves. Significance was
defined at the P < 0.05 level. All the analyses were per-
formed by MATLAB (The MathWorks).
In silico miRNA targets identification
Several prediction target tools were examined using the
web server tool MirWalk3 (http://zmf.umm.uni-heidel-
berg.de/apps/zmf/mirwalk2/).
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Given a list of microRNAs, we downloaded the experi-
mentally validated miRNA-target interactions from miR-
TarBase web site (Release 7.0, September 2017). Then,
we built a network of miRNA-target interactions by
using R programming language (Release 3.4.4, March
2018) for network visualization and analysis [25].
Fig. 1 miR-96-5p upregulation is stronger in TP53 mutated HNSCC and predicts local recurrence in HNSCC patients. a Box plot showing expression
level of miR-96-5p in the tumoral and normal tissues from IRE cohort. b Box plot of the expression level of miR-96-5p in the tumoral and normal
tissues from TCGA cohort. c Kaplan–Meier (KM) analysis showing correlation between the expression level of miR-96-5p and recurrence-free survival in
the HNSCC patients from IRE cohort. d-e Comparison of miR-96-5p expression between TP53 mutated and wild type tumors from matched samples
IRE cohort (d) and from matched samples TCGA cohort (e). N: number of samples, FC: Fold change, p: p-value
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Fig. 2 (See legend on next page.)
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Pathway enrichment analysis
Pathway enrichment analysis was performed using the
program http://mirwalk.umm.uni-heidelberg.de/. Posi-
tively and negatively correlated genes to miR-96-5p ex-
pression from TCGA dataset were selected and used for
the program as explained in the relative paragraph of
the results (Additional file 1: Table S1). For the cut-off,
in the program the following criteria were used: mini-
mum overlap with input list: 10 genes and P < 0.05.
Results
miR-96-5p upregulation correlates with TP53 status and
predicts local recurrence development in HNSCC patients
In our previous studies, we have identified TP53-mutation
associated alterations of miRNAs expression in HNSCC
tissues [14, 15, 24]. In particular, we demonstrated that
the expression of a specific TP53-mutation associated
four-miRNAs signature predicts local recurrence insur-
gence in tumors and matched histologically tumor-free
peritumor tissues from HNSCC patients [14, 24].
miR-96-5p was included in this signature and because its
oncogenic activity in HNSCC cells has not been deeply
characterized yet, here we decided to focus our attention
on this miRNA.
We first evaluated the expression level of the
miR-96-5p in matched tumoral and normal tissues col-
lection from head and neck squamous cell carcinoma
patients of IRE and TCGA cohorts (Fig. 1a-b).
The expression level of miR-96-5p was significantly
higher in the tumoral tissues in comparison with the
non-tumoral tissues from 66 matched samples of IRE
cohort (Fig. 1a) and from 42 matched samples of TCGA
cohort (Fig. 1b). Additionally, as shown in Fig. 1c and in
agreement with our previous data [14, 15], we showed
that high expression of miR-96-5p predicts local recur-
rence development in HNSCC patients by Kaplan-Meier
(KM) analysis. Next, to further confirm that the expres-
sion level of this miRNA is associated to TP53 status, we
evaluated its expression level in the matched subgroup
tumor versus normal tissues of HNSCC patients carrying
TP53 mutations versus the TP53 wild type. As shown in
Fig. 1d-e, we found that its up-regulation in tumors versus
non-tumoral tissues was significantly stronger in the sub-
set of mutant p53 patients. As mutation in TP53 tumor
suppressor gene is the most frequently detectable genetic
alterations (about 70–80%) reported in HNSCC [10], we
decided to specifically assess the miR-96-5p oncogenic ac-
tivity TP53 mutated context HNSCC cell lines.
Overexpression of miR-96-5p promotes cell migration,
but not cell proliferation in HNSCC cells
In order to investigate the miR-96-5p oncogenic activity
TP53 mutated context, we performed a series of experi-
ments to evaluate migration, survival, proliferation, clono-
genicity and sensitivity to adjuvant therapy in two selected
HNSCC cell lines, Cal 27 and FaDu [26].
First, we assessed the influence of miR-96-5p on cell mi-
gration, by transfection of the miR-96-5p mimic,
miR-96-5p inhibitor or relative negative control into Cal
27 and FaDu cell lines. The efficiency of miR-96-5p mimic
and inhibitor transfection on HNSCC cells was evaluated
by RT-qPCR on Cal 27 (Fig. 2a, c) and FaDu (Fig. 2e, g)
cells. The effect of miR-96-5p on HNSCC cell migration
was analyzed by Transwell migration assay and the migra-
tory ability of the transfected cells was measured and
compared with that of negative control (NC) at 72 and 96
h post-transfection. As shown in Fig. 2b and f, overexpres-
sion of miR-96-5p, significantly increased cell migration of
both cell lines. Conversely, down-regulation of miR-96-5p
inhibited the cell migration of Cal 27 (Fig. 2d) and FaDu
(Fig. 2h) cells. We next evaluated the impact of miR-96-5p
on cell proliferation and clonogenicity by performing clo-
nogenic assay, cell cycle analysis and growth curve. Col-
lectively, the results showed that miR-96-5p did not affect
cell proliferation but did affect cell migration. (Additional
file 2: Supplementary material and methods and Add-
itional file 3: Figure S1).
miR-96-5p expression enhances resistance to
radiotherapy and cisplatin-based chemotherapy in HNSCC
cells
Radio and chemo-resistance is a critical issue in HNSCC
treatment and is frequently related to local recurrence
development [7, 27]. To this purpose we investigated the
effect of miR-96-5p expression on radio- and
chemo-sensitivity by performing cell viability and clono-
genic assays on HNSCC cell lines. At 48 h after transfec-
tion with miR-96-5p mimic or inhibitor, Cal 27 and
FaDu cells were treated with 2Gy dose of irradiation and
the cell viability was assessed by ATPlite assay. The effi-
ciency of transfection was evaluated by RT-qPCR (Fig. 3a,
c, e and g). As shown in Fig. 3b and d, overexpression of
(See figure on previous page.)
Fig. 2 High expression of miR-96-5p promotes cell migration in HNSCC cell lines carrying mutant p53 protein. Two HNSCC cell lines (Cal 27, FaDu) were
transfected with miR-96-5p mimic and inhibitor. The efficiency of transfection was evaluated by RT-qPCR in Cal 27 (a-c) and FaDu (e-g) cells. b, d, f, h
Representative micrographs of transwell migration in Cal 27 (b-d) and FaDu (f-h) cell lines, DAPI staining was used to quantify the migrated cells on the
outer surface of the filter. Histogram shows the number of migrated cells after using miR-96-5p mimic (b, f) and miR-96-5p inhibitor (d, h) in the Cal 27
and FaDu cell lines. Bars show the means of at least two experiments performed in triplicate. The p-value refers to matched control versus miR-96-5p
mimic and miR-96-5p inhibitor transfected samples.*P< 0.05; **P< 0.001; ***P< 0.0001. NC: Negative control
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Fig. 3 (See legend on next page.)
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miR-96-5p increased cell radio-resistance respectively in
Cal 27 and FaDu cell lines. On the contrary, down regu-
lation of miR-96-5p enhanced sensitivity to irradiation
by decreasing cell viability (Fig. 3f, h) and the number of
colonies formed in the cells treated with 2Gy in com-
parison with the negative control (Fig. 3i, j).
Next, we analyzed whether miR-96-5p expression
could affect the sensitivity of HNSCC cells to
cisplatin-based chemotherapy. After 48 h of transfection
with miR-96-5p mimic or miR-96-5p inhibitor, Cal 27
and FaDu cells were treated with different concentra-
tions of cisplatin (0.5, 1, 2, 4, 8 μg/ml) and the cell viabil-
ity was assessed by ATPlite assay. The efficiency of
transfection in Cal 27 (Fig. 4a, c) and FaDu (Additional
file 4: Figure S2a, S2c) cells was detected by RT-qPCR.
ATPlite assay indicated that overexpression of
miR-96-5p decreased cell sensitivity to cisplatin by in-
creasing cell viability in Cal 27 (Fig. 4b) and FaDu (Add-
itional file 4: Figure S2b) cells. Indeed, changes in IC50
value were found in the transfected cells according to
the presence of cisplatin treatment; overexpression of
miR-96-5p led to an increase of IC50 value from 1.252
uM to 2.560 uM in comparison with the negative con-
trol in Cal 27 cells (Fig. 4b) and from 4.182 uM to 6.568
uM in FaDu cells (Additional file 4: Figure S2b). Con-
versely, down regulation of miR-96-5p expression en-
hanced cell sensitivity to cisplatin by decreasing cell
viability after cisplatin treatment in Cal 27 (Fig. 4d) and
FaDu (Additional file 4: Figure S2d) cells. As shown in
Fig. 4d, IC50 value changed from 1.690 uM to 0.9435
uM compared to negative control for Cal 27 and from
3.890 uM to 2.016 uM for FaDu (Additional file 4: Fig-
ure S2d) cell lines. The correlation between miR-96-5p
expression level and chemo-sensitivity was also con-
firmed by clonogenicity assay. As shown in Fig. 4e for
Cal 27 cells and Additional file 4: Figure S2e for FaDu
cells, downregulation of miR-96-p5 expression caused a
decrease of the colony formation ability in cells treated
with 0.5 and 1 μg/ml concentration of cisplatin com-
pared to the transfected cells not treated with cisplatin.
Identification of mRNAs correlated to miR-96-5p in
HNSCC tumors carrying mutant p53 protein
To explore the functional output of the miR-96-5p de-
regulation in HNSCC tissues specifically in a mutant
p53 context, we combined the information of miRNA
expression levels with the gene expression profiles of
176 HNSCC patients carrying missense p53 mutations
from TCGA cohort. First, we excluded all the mRNAs
that resulted correlated to miR-96-5p expression also in
HNSCC subgroup carrying wild type p53 from TCGA
cohort. Then, we selected only the genes positively or
negatively correlated with miR-96-5p according to a
Pearson and Spearman’s correlation coefficient higher
than 0.3 in absolute value predicted by MirWalk3. We
obtained 214 mRNAs, of which 58 positively and 156
negatively correlated to the expression of miR-96-5p in
tumor tissues of HNSCC patients from TCGA cohort
(Additional file 1: Table S1).
Functional classification of these genes showed enrich-
ment for genes belonging to various cancer-related path-
ways; many of them are in agreement with the
miR-96-5p biological role related to the cell migration
and resistance to adjuvant therapy demonstrated in
HNSCC cells, as the focal Adhesion, extracellular matrix
organization and PI3K-Akt-mTOR-signaling pathway
(Table 1). Among the most significant predicted path-
way, we found the PI3K-Akt pathway, which has
emerged as one of the most frequently altered in cancer
including HNSCC [28, 29]. This pathway plays a crucial
role in regulating a broad range of cellular functions in-
cluding cell growth, death, adhesion and migration,
chemo-resistance, and radio-resistance in cancer cells
[30]. One of the main inhibitor of the PI3K/AKT/mTOR
pathway is PTEN, which is included in the list of
mRNAs negatively correlated to miR-96-5p expression
(Additional file 1: Table S1 sheet 1).
PTEN is a direct target of miR-96-5p
As described above, among the genes predicted as puta-
tive targets of miR-96-5p (Additional file 1: Table S1 sheet
1), we identified PTEN. By interrogating HNSCC TGCA
we found that PTEN expression is reduced in almost 15%
of the patients. This is due either genetic alterations such
as mutations and deletions or yet undiscovered epigenetic
mechanisms that might also include miRNA targeting
(Fig. 5a, b) [31]. To validate whether the PTEN mRNA is
a direct target of miR-96-5p through the binding to its
cognate site on the 3’UTR of PTEN (accordingly to Mir-
Walk3 Fig. 5c), we performed a luciferase reporter assay.
(See figure on previous page.)
Fig. 3 miR-96-5p expression affects radiosensitivity of Cal 27 and FaDu cells. Cal 27 and FaDu cells were transfected with miR-96-5p mimic and
inhibitor. After 48 h, cells were treated with 2Gy dose of irradiation. a-d RT-qPCR analysis showing efficiency of miR-96-5p mimic transfection in
Cal 27 cells (a) and in FaDu cells (c). Cell viability after transfection and radiation of Cal 27 (b) and FaDu (c) cells has been assessed by ATPlite
assay. e-h RT-qPCR analysis showing efficiency of miR-96-5p inhibitor transfection in Cal 27 cells (e) and in FaDu (g) cells. Cell viability after transfection and
radiation of Cal 27 (f) and FaDu (h) cells has been assessed by ATPlite assay. i-j Colony formation assay of Cal 27 (i) and FaDu (j) cells after transfection with
miR-96-5p inhibitor and radiation treatment at 2Gy dose. Histogram bars show the means of at least three experiments performed in triplicate. *P< 0.05;
**P< 0.001. NC: Negative control
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Wild type 3’UTR of PTEN cloned into the psi-CHECK2
vector was co-transfected with miR-96-5p mimic or con-
trol mimic into the H1299 cells. As shown in Fig. 5d, we
found that miR-96-5p significantly reduced the relative l-
uciferase activity of the wild-type reporters. Next, we
checked the activity of these reporters when we
co-transfected the H1299 cells with PTEN-
CDS-psi-CHECK2 vector that did not contain any cognate
binding consensus for miR-96-5p.
As shown in Fig. 5e, no significant change in the rela-
tive luciferase activity was detected. These data indicated
that PTEN is a direct target of miR-96-5p and its bind-
ing is specifically located in 3’UTR region of PTEN
mRNA. It also appeared that miR-96-5p targeting of
PTEN mRNA does not occur through the binding to
PTEN CDS (Fig. 5e). Next, to further confirm these data
and the involvement of miR-96-5p expression in the
control of PI3K-AKT pathway activation by PTEN, we
evaluated by western blot analysis, the expression level
of PTEN, pAKT S473 and AKT proteins in the Cal 27
cells transiently transfected with miR-96-5p inhibitor or
control inhibitor. The efficiency of transfection in Cal 27
was detected by RT-qPCR (Fig. 5f ). As shown in Fig. 5g,
by reducing the ectopic expression of miR-96-5p, we
observed an increase in the protein level of PTEN, a
decrease in the expression level of pAKT S473 and no
change in the expression level of AKT. These data con-
firm that miR-96-5p can directly target PTEN and
affects PI3K/AKT pathway. The inverse correlation be-
tween the expression level of PTEN protein and
miR-96-5p level was confirmed also in FaDu cell line
(Additional file 5: Figure S3).
PTEN depletion recapitulates the biological effects of
miR-96-5p overexpression in HNSCC cells
To investigate whether miR-96-5p may promote cell mi-
gration and cell resistance to therapy by silencing the
PTEN expression in HNSCC cells, we assessed the effect
of PTEN depletion on cell migration, clonogenicity and
sensitivity to radiotherapy by the transfection of PTEN
siRNA for 48 h in Cal 27 cell line. The efficient knock-
down of PTEN mRNA in Cal 27 cells is shown in Fig. 6a.
By performing migration assay in Cal 27 cells depleted
for PTEN, we observed a significant increase in the cell
migration similar to miR-96-5p overexpression (Fig. 6b).
To explore whether miR-96-5p regulation of cell migra-
tion is executed in a PTEN-dependent manner, we
co-transfected cells with miR-96-5p inhibitor and siRNA
of PTEN (siPTEN). As shown in Fig. 6b, compared with
cells transfected with the relative negative control
(si-scr/NC), the cells co-transfected with miR-96-5p in-
hibitor and siPTEN exhibited a lower increase of cell mi-
gration respect the only siRNA of PTEN (Fig. 6b),
demonstrating that siRNA mediated knockdown of
PTEN could partially rescue the inhibitory effect of
miR-96-5p inhibitor for the cell migration. We next ex-
plored the role of PTEN silencing in the colony forma-
tion ability and in the sensitivity to radiotherapy. As
expected and shown in Fig. 6c, no significant change in
colonies forming between control and siPTEN trans-
fected cells has been detected in Cal 27 cells. On the
contrary, we observed an effect on cell sensitivity to
radiotherapy; after 48 h of transfection with siRNA of
PTEN, Cal 27 cells were treated with 2Gy dose of irradi-
ation and the cell viability was assessed by ATPlite assay
(Fig. 6d). As shown in Fig. 6 d, down-regulation of
PTEN increased the cell radio-resistance. We further
confirmed these data by performing a colony formation
(See figure on previous page.)
Fig. 4 miR-96-5p expression affects the sensitivity of Cal 27 cells to chemotherapy. Cal 27 cells were transfected with miR-96-5p mimic and
inhibitor. After 48 h cells were treated with different concentration of cisplatin (0.5,1,2,4,8 μg/ml). a RT-qPCR data showing efficiency of miR-96-5p
mimic transfection. b Cell viability analysis of Cal 27 cells treated with miR-96-5p mimic and different concentrations of cisplatin in comparison
with the negative control. c RT-qPCR data showing efficiency of miR-96-5p inhibitor transfection. d Cell viability analysis of Cal 27 cells treated
with miR-96-5p inhibitor and different concentration of cisplatin in comparison with the negative control. e Colony formation assay performed
on Cal 27 cells treated with miR-96-5p inhibitor and different concentration of cisplatin in comparison with the negative control. Histogram bars
show the means of at least three experiments performed in triplicate.*P < 0.05; **P < 0.001. NC: Negative control, CDDP: Cisplatin
Table 1 Pathways enrichment analysis of genes correlated to
miR-96-5p in a mutant TP53 context
Pathway p-value
Focal adhesion - Homo sapiens (human) 2.10E-05
Focal Adhesion 3.02E-05
Signaling by Receptor Tyrosine Kinases 3.29E-05
Regulation of actin cytoskeleton- Homo sapiens (human) 0.00016
Extracellular matrix organization 0.000163
PI3K-Akt signaling pathway - Homo sapiens (human) 0.000829




PI3K-Akt Signaling Pathway 0.002061
Human papillomavirus infection - Homo sapiens (human) 0.004174
Pathways in cancer - Homo sapiens (human) 0.008498
Axon guidance 0.008829
Hemostasis 0.023744
Post-translational protein modification 0.028931
P < 0.05 was considered significant
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assay. As shown in Fig. 6e, a lower expression of PTEN
led to an increase of colonies number formed in the cells
treated with 2Gy in comparison with the negative control.
Interestingly, depletion of PTEN expression rendered
Cal27 cells less prone to Cisplatin-induced cell killing
(Fig. 6f). Collectively these findings clearly describe that
PTEN is a mediator of chemo-radiotherapy treatment for
HNSCC cells and that its miR-96-5p-mediated depletion
contributes to HNSCC radio-chemoresistance.
Discussion
Despite advances in treatments, the overall mortality of
HNSCC has remained unchanged over the past decades.
The lethality of HNSCC is mainly due to difficulties in
detecting it at an early stage and the lack of effective
treatments for patients in advanced stages. Therefore, it
is crucial understanding the molecular mechanisms in-
volved in HNSCC progression and discovering more ef-
fective biomarkers of HNSCC to improve diagnosis,
treatment choice and prevention of the disease.
Among the best promising biomarkers, miRNAs, are
emerging as an appealing tool for screening, diagnosis,
prognosis, monitoring tumor progression, assisting in
designing the proper treatment for patients and predict-
ing drug response [18]. In addition, the correction of cel-
lular miRNA expression levels might emerge as a
potential therapeutic strategy [32, 33]. We previously
showed that altered expression of 12 microRNA
TP53-dependent signature in tumors and 4 microRNA
signature in matched peritumoral tissues of HNSCC are
able to predict local recurrence in patients [14, 24]; both
of these signatures include miR-96-5p. In addition, this
miR may also work as an independent prognostic factor
for local recurrence development specifically in the oral
cancer subgroup of HNSCC [15] and it was identified
among a pool of miRNAs, which is able to predict ma-
lignant transformation in oral leukoplakia [22]. Several
studies have shown that miR-96-5p could act as an
oncogene [34–38] or tumor suppressor [39, 40] accord-
ing to different kinds of cancer. In HNSCC, there is
short evidence showing its ability to work as an onco-
gene. Chung-Hsien Chou BS et al. showed that concord-
ant up-regulation of miR-31, miR-96, and miR-182 may
increase migration and invasion of HNSCC cells by
co-targeting NUMB mRNA [41], while Yan Guo et al.
demonstrated the involvement of miR-96 in the Tongue
Cancer tumorigenesis by promoting the repression of
MTSS1 mRNA expression [42].
However, no evidences about the role of miR-96-5p in
chemo/radio-resistance of HNSCC have been shown yet
and in this study, we provided a novel molecular insight
of miR-96-5p impacting HNSCC by suppressing PTEN
expression. In particular, as miR-96-5p expression was
associated with TP53 status [14], we assessed its activity
specifically on HNSCC cells carrying mutant p53, which
is the most frequently mutated gene in HNSCC (about
80% in HPV negative HNSCC patients from TCGA
cohort).
We showed that miR-96-5p was up-regulated in tu-
mors versus normal tissues from two different HNSCC
cohorts and that its deregulation was significantly stron-
ger in a mutant p53 context. In addition, up-regulation
of miR-96-5p may promote cell migration and resistance
to chemo and radio-therapy without affecting cell prolif-
eration and clonogenicity. Cook et al., recently reported
that gain of function mutp53 carrying colon cancer cells
released miR-1246 enriched exosomes which instructed
tumor associated macrophages toward cancer progres-
sion and metastasis [43]. This suggests that the analysis
of exosomal circulating miRNAs, such as miR-96-5p,
might provide additional insights regarding the molecu-
lar events underlying relapse of HNSCC patients.
Additionally, by the pathway enrichment analysis per-
formed using the list of mRNAs negatively and positively
correlated to miR-96-5p expression in the 176 HNSCCs
carrying mutant p53 from TCGA cohort, we identified
PI3K/AKT signaling pathway as one of the most signifi-
cant pathways linked to miR-96-5p molecular activity. It
is the most frequently altered oncogenic pathway in
HNSCC playing a crucial role in regulating a broad
range of cellular functions including cell migration,
chemo-resistance, and radio-resistance [28–30]. In
addition and more interestingly, several evidences sug-
gest that PI3K pathway is a promising therapeutic target
in HNSCC [44, 45]. Its activation is negatively regulated
by a lipid phosphatase, phosphatase and tensin homolog
(PTEN), which catalyzes the dephosphorylation of PIP3
(See figure on previous page.)
Fig. 5 miR-96-5p targets PTEN and affects PI3K activation. a PTEN distribution in tumoral samples with altered PTEN (mutated or deleted), with
not altered PTEN and in normal samples. b PTEN distribution in tumoral samples with altered PTEN or with down-regulation of PTEN higher than
0.5 log2 folds and in normal samples. c Position of the miR-96-5p target site in the 3’UTR of PTEN predicted by miRwalk 3.0. d Luciferase activity
of PTEN-3’UTR-WT reporter gene in H1299 cell line. Cells were transiently transfected with miR-96-5p mimic or control mimic. The histogram bars
show the means of three experiments performed in duplicate, **P < 0.001. e Luciferase activity of PTEN-CDS-WT reporter gene in H1299 cell line
which were transiently transfected with miR-96-5p mimic or control mimic. Bars show the means of two experiments performed in triplicate.
f RT-qPCR graph showing miR-96-5p expression level in Cal 27 cell line after miR-96-5p inhibitor transfection, **P < 0.001. g Western-blot analysis
of PTEN, p-AKT and AKT protein expression level in Cal 27 cells that were transfected with miR-96-5p inhibitor or control inhibitor. NC: Negative
control, T: tumor
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Fig. 6 PTEN silencing mimics the biological effects of miR-96-5p overexpression in Cal 27 cells. a Western-blot analysis of PTEN protein expression
level in Cal 27 cells transfected with siPTEN and scrambled siRNA as negative control. b Representative histogram of transwell migration assay of Cal
27 cells treated with siPTEN and scrambled siRNA and co-transfected cells with miR-96-5p inhibitor and siPTEN or control inhibitor and scrambeld
siRNA. Bars show the means of at least two experiments performed in triplicate. The p-value refers to matched control inhibitor and scrambled siRNA
versus miR-96-5p inhibitor and siPTEN transfected samples.*P < 0.05; **P < 0.001; ***P < 0.0001. c Colony formation assay of Cal 27 cells treated with
siPTEN and scrambled siRNA. Histogram shows the number of migrated cells after using siPTEN and scrambled siRNA. Bars show the means of at least
two experiments performed in triplicate. The p-value refers to matched control versus siPTEN transfected samples.*P < 0.05; **P < 0.001; ***P < 0.001.
d-e Cell viability (d) and cell colony (e) analyses of Cal 27 cells transfected with siPTEN and treated with radiation at the dose of 2Gy. f Cell viability
analysis of Cal 27 cells transfected with siPTEN and treated with different concentration of cisplatin in comparison with the negative control. siSCR: SCR
siRNA, siPTEN: PTEN siRNA
Fig. 7 Proposed model depicting the oncogenic effects of the miR-96-5p/PTEN alterated expression in HNSCC . As shown in the miRNAs-validated
targets interaction networks, PTEN is a direct target shared by both miRNA signatures in the tumoral and peritumoral HNSCC tissues. In particular, the
oncogenic miR-96-5p directly binds to PTEN 3’UTR then commences the signaling cascade and leads to down regulation of the expression level of
PTEN therefore, cell migration and resistance to radiotherapy and chemotherapy increase
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to PIP2 and governs numerous cellular processes [46].
Down-regulation of PTEN expression due to either gen-
etic alterations such as mutations and deletions or epi-
genetic inactivation accounts for around 15% of TGCA
HNSCC patients. Here, we propose that the tight target-
ing of PTEN expression through aberrant expression of
miRNAs including miR-96-5p might occur in the peritu-
moral tissues that are histologically undistinguished
from matched non-tumoral tissues thereby suggesting
PTEN reduced expression as an early event in HNSCC
tumorigenesis (Fig. 7). This miRNA-mediated downreg-
ulation occurs also in tumoral tissues in which the num-
ber of the miRNAs (including miR96-5p) targeting
directly PTEN is higher than those involved in peritu-
moral tissues. In aggregate these findings might suggest
that persistent reduction of PTEN expression due to ab-
errant modulation of miRNAs is necessary for early and
late stages of HNSCC tumorigenesis.
To summarize and as shown in our hypothetical
model (Fig. 7), our study provided the first evidence that
miR-96-5p played a significant role in enhancing resist-
ance to therapy through inhibition of PTEN in HNSCC.
Despite that, there might be other targets of miR-96-5p,
which could also affect the sensitivity to chemo and
radiotherapy, also in wild type TP53 context.
Therefore, future studies are required to identify add-
itional targets and pathways of miR-96-5p and its correl-
ation with target therapies ongoing in clinical trial for
HNSCC treatment, as PI3K inhibitors.
Conclusions
Taken together, these results indicate that miR-96-5p
could be a promising biomarker to monitor treatment
response in HNSCC and identify patients resistant to
chemo-radiotherapy. In addition, therapeutic strategy
targeting miR-96-5p levels could potentially be beneficial
to overcome chemo/radio-resistance in HNSCC.
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